Home › Valeant raises offer for Dendreon assets to US$400 million to remain lead bidder
 

Keywords :   


Valeant raises offer for Dendreon assets to US$400 million to remain lead bidder

2015-02-05 18:29:47| Biotech - Topix.net

Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million. The Quebec-based company is the lead bidder in an auction supervised by a U.S. bankruptcy court.

Tags: offer lead million remain

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
More »